Circulating Mir-146A Expression Predicts Early Treatment Response to Imatinib in Adult Chronic Myeloid Leukemia
- 1 February 2021
- journal article
- research article
- Published by SAGE Publications in Journal of Investigative Medicine
- Vol. 69 (2) , 333-337
Abstract
This study aimed to investigate the prognostic role of circulating miR-146a in the prediction of early response to imatinib treatment in patients with chronic myeloid leukemia (CML). Sixty patients with CML and 20 healthy controls were recruited in this study. BCR-ABL was assessed by quantitative rt-PCR at days 0 and 90 of imatinib therapy. Circulating miR-146a levels were assessed by quantitative rt-PCR at days 0, 14 and 90 of imatinib therapy for patients and once for controls. At day 90 of treatment, treatment response was achieved in 48 patients (80.0%). Responders had significantly lower baseline Sokal score when compared with non-responders. They also had significantly lower BCR-ABL expression at day 90 of treatment. The circulating miR-146a level was significantly lower in patients with CML than in healthy subjects and showed a significant rise after 14 days of imatinib treatment and an inverse correlation with BCR-ABL expression levels at 90 days. Using multivariate logistic regression analysis, baseline BCR-ABL (%) (OR (95% CI) 1.09 (1.03 to 1.016), p=0.006) and miR-146a at 14 days (OR (95% CI) 0.002 (0.0 to 0.09), p=0.001) were significant predictors of treatment response. Using ROC curve analysis, it was found that miR-146a expression at 14 and 90 days could distinguish responders from non-responders (AUC (95% CI) 0.849 (0.733 to 0.928) and 0.867 (0.755 to 0.941), respectively). This study reported for the first time that measurement of the circulating miR-146a expression at 14 days can predict the early response to imatinib treatment in patients with CML. Thus, this work indicates that miR-146a should be investigated in the setting of treatment response to other tyrosine kinase inhibitors.Keywords
This publication has 32 references indexed in Scilit:
- Role of serum Metadherin mRNA expression in the diagnosis and prediction of survival in patients with colorectal cancerMolecular Biology Reports, 2020
- Oct4 expression in gastric carcinoma: association with tumor proliferation, angiogenesis and survivalJournal of the Egyptian National Cancer Institute, 2019
- Serum HOX transcript antisense RNA expression as a diagnostic marker for chronic myeloid leukemiaThe Egyptian Journal of Haematology, 2019
- Management of imatinib-resistant patients with chronic myeloid leukemiaTherapeutic Advances in Hematology, 2012
- Molecular biology of bcr-abl1–positive chronic myeloid leukemiaBlood, 2009
- Oncomirs — microRNAs with a role in cancerNature Reviews Cancer, 2006
- Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA TargetsCell, 2005
- Biology of chronic myelogenous leukemia—signaling pathways of initiation and transformationHematology/Oncology Clinics of North America, 2004
- Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative target genesNucleic Acids Research, 2003
- Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemiaProceedings of the National Academy of Sciences, 2002